Research Projects

This database contains information on EU funded dementia research projects, undertaken since 2007. It is the product of a mapping exercise of European funding programmes for dementia research conducted by Alzheimer Europe in 2020. This database is not an exhaustive resource of information. It contains information about dementia research projects that are funded by European programmes including FP7, H2020, IMI, JPND, AAL and the third EU Health programme. The mapping exercise and database were expanded in 2025, to include projects funded under Horizon Europe (including IHI). For these projects, the database reports the maximum contribution from the European Commission rather than the total project budget, so funding figures may not be directly comparable across all entries.
For an overview of projects, Alzheimer Europe is involved in, visit: https://www.alzheimer-europe.org/our-work/current-work

Filters

(Clear all)

Dementia: Intersectorial Strategy for Training and Innovation Network for Current Technology (DISTINCT)

DISTINCT

The main aim of DISTINCT will develop a premier quality multi-disciplinary, multi-professional and intersectorial education and training research framework for Europe aimed at improving technology and care for people with dementia and their carers, and to use coherent themes an.d interrelated ESRs within DISTINCT to provide the evidence to show how...

Funding Programme
Start Date
End Date
Total Funding
€ 3 998 048
European Countries Involved

Disrupting the Migraine continuum of care for resource constrained settings

TARA

Chronic migraine is defined as a headache persistent for more than 3 months or a severe headache persistent for more than 15 days within a month. It affects approximately 2% of the world population. The World Health Organization classifies severe migraine attacks as among the most disabling illnesses, comparable to dementia and quadriplegia...

Funding Programme
Start Date
End Date
Total Funding
€ 4 380 708
European Countries Involved

Do nanoparticles induce neurodegenerative diseases? Understanding the origin of reactive oxidative species and protein aggregation and mis-folding phenomena in the presence of nanoparticles

NEURONANO

As the use of nanoparticles becomes more prevalent, it is clear that human exposure will inevitably increase. Considering the rapidly ageing European population and the resulting increase in the incidence of neurodegenerative diseases, there is an urgent need to address the risk presented by nanoparticles towards neurodegenerative diseases. It is...

Funding Programme
Start Date
End Date
Total Funding
€ 4 823 050
European Countries Involved

European Patient Organizations in Knowledge Society

EPOKS

The last two decades have witnessed the increasing role of patient, user and civil society organizations (POs and CSOs) in the production of knowledge on diseases and health problems. Rich and detailed studies have shown that this phenomenon entails new forms of activism. It also questions the modes of governance of knowledge, as well as the role...

Funding Programme
Start Date
End Date
Total Funding
€ 1 129 013
European Countries Involved

European Standardised Process Approach to Cognitive Evaluation in older people

E-SPACE

During this fellowship at Dublin City University (Ireland), the researcher will enhance, significantly, the clinical utility of existing traditionally used cognitive tests, particularly as it relates to the early detection and accurate diagnosis of mild cognitive impairment (MCI) and dementia. Cognitive difficulties represent the hallmark of many...

Funding Programme
Start Date
End Date
Total Funding
€ 187 866
European Countries Involved

In-Touch: Implementation of a person-centered palliative care iNtervention To imprOve comfort, QUality of Life and social engagement of people with advanced dementia in Care Homes

In-Touch

Challenge. Caring for the increasing numbers of people across Europe with advanced dementia and palliative care needs who live in care homes is difficult and demanding. People with advanced dementia can be immobile, non-verbal and unable to take part in day-to-day activities. They can be unsettled or agitated, with low quality-of-life and elevated...

Funding Programme
Start Date
End Date
Total Funding
€ 5 723 637

INdependent LIving support Functions for the Elderly

IN LIFE

The number of elderly living with cognitive impairment is growing rapidly due to increasing life expectancy. The percentage of those who live alone depends upon the condition (i.e. roughly 30% of those diagnosed with dementia) but the majority would like to live in their own home or with family, provided that it is safe, comfortable, and cost...

Funding Programme
Start Date
End Date
Total Funding
€ 3 761 729
European Countries Involved

Innovative Midlife Intervention for Dementia deterrence

IN-MINDD

The European costs of dementia were estimated €177 billion and there is a growing gap between burden and budget. The debilitation associated with dementia makes it the most feared of conditions related to ageing . Modelling studies have estimated that if obesity rates dropped by 5%, dementia prevalence rates would be lower by 6% and a decline in...

Funding Programme
Start Date
End Date
Total Funding
€ 3 825 936
European Countries Involved

Integrated Technology Ecosystem for ProACTive Patient Centred Care

ProACT

ProACT targets Europe’s 50 million multimorbid patients to proactively self-manage and offset the EU’s annual €700billion cost of chronic disease management. ProACT aims at providing and evaluating an open application programming interface to integrate a variety of new and existing technologies to advance ‘home based’ integrated care (IC). Cloud...

Funding Programme
Start Date
End Date
Total Funding
€ 4 876 709
European Countries Involved

Integrative structural biology of pathological tau protein, an appealing therapeutic target for Alzheimer´s disease modifying drugs

InterTAU

There is an enormous and unmet medical need to find efficient methods of prevention, diagnosis and disease-modifying therapies for tauopathies, including Alzheimer’s disease. The common molecular denominator of tauopathies are pathological forms of tau protein. Tau pathology relates to conformational changes during oligomerization and assembly...

Funding Programme
Start Date
End Date
Total Funding
€ 1 062 600
European Countries Involved

Investigation of Cerebral Autosomal Dominant Arteriopathy with Sub-cortical Infarcts and Leukoencephalopathy (CADASIL) using induced pluripotent stem cell modelling and targeted therapeutic research

CADASIL-iMATTR

CADASIL, a rare disease of the small blood vessels, is caused by mutations in NOTCH3 and can cause cognitive decline leading to dementia. Vascular disease is the second most common cause of dementia with the burden set to increase with population aging. Insights into CADASIL will prove instrumental in understanding and treating the vascular...

Funding Programme
Start Date
End Date
Total Funding
€ 278 571
European Countries Involved

Label Free Nanoscopy Using Infra Red

LANIR

Every year, Alzheimer's disease (AD) affects about 800,000 new patients in Europe and directly causes 50% of dependency of aged persons. Currently there is no test to diagnose this disease. There is a great need to improve outcomes for patients with lung cancer which causes between 15-28% of all cancer deaths in Europe. Chemical and structural...

Funding Programme
Start Date
End Date
Total Funding
€ 5 456 348
European Countries Involved
 
Acknowledgement
Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).